Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6502599rdf:typepubmed:Citationlld:pubmed
pubmed-article:6502599lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:6502599lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6502599lifeskim:mentionsumls-concept:C1522721lld:lifeskim
pubmed-article:6502599lifeskim:mentionsumls-concept:C0004481lld:lifeskim
pubmed-article:6502599lifeskim:mentionsumls-concept:C0055533lld:lifeskim
pubmed-article:6502599lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:6502599pubmed:issue12lld:pubmed
pubmed-article:6502599pubmed:dateCreated1985-1-22lld:pubmed
pubmed-article:6502599pubmed:abstractTextA series of A-ring heterocyclic steroids has been prepared and tested for inhibition of rat prostatic steroid 5 alpha-reductase in vitro. Strikingly high inhibitory activity was found with a group of 17 beta-substituted 4-methyl-4-aza-5 alpha-androstan-3-ones. These compounds were prepared from 3-keto-delta 4-precursors by oxidative (O3 or NaIO4-KMnO4) A-ring cleavage followed, in turn, by ring closure with an amine and hydrogenation over platinum catalyst. Other A-ring azasteroids were made by Beckmann rearrangement of oximes of 2-oxo-A-nor, 3-oxo- and 4-oxo-5 alpha-androstanes. An A-nor-2-oxo-3-azasteroid was prepared by oxidative decarbonylation of a precursor 2,3-dioxo-4-azasteroid with m-chloroperbenzoic acid. A-ring modifications of the 4-azasteroids included delta 1-unsaturation, 2- and 4-substituents, and 3-carbonyl replacements. Side chains at the 17-position were varied with an emphasis on carboxylate derivatives (salts, esters, and amides).lld:pubmed
pubmed-article:6502599pubmed:languageenglld:pubmed
pubmed-article:6502599pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:citationSubsetIMlld:pubmed
pubmed-article:6502599pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6502599pubmed:statusMEDLINElld:pubmed
pubmed-article:6502599pubmed:monthDeclld:pubmed
pubmed-article:6502599pubmed:issn0022-2623lld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:BrooksJ RJRlld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:BermanCClld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:RasmussonG...lld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:PrimkaR LRLlld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:ReynoldsG FGFlld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:UtneTTlld:pubmed
pubmed-article:6502599pubmed:authorpubmed-author:JobsonR BRBlld:pubmed
pubmed-article:6502599pubmed:issnTypePrintlld:pubmed
pubmed-article:6502599pubmed:volume27lld:pubmed
pubmed-article:6502599pubmed:ownerNLMlld:pubmed
pubmed-article:6502599pubmed:authorsCompleteYlld:pubmed
pubmed-article:6502599pubmed:pagination1690-701lld:pubmed
pubmed-article:6502599pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:meshHeadingpubmed-meshheading:6502599-...lld:pubmed
pubmed-article:6502599pubmed:year1984lld:pubmed
pubmed-article:6502599pubmed:articleTitleAzasteroids as inhibitors of rat prostatic 5 alpha-reductase.lld:pubmed
pubmed-article:6502599pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6502599pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:6502599lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6502599lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6502599lld:pubmed